Furthermore, to explore the therapeutic potential of targeting the USP10/B7‐H4 axis in TNBC, we investigated the anti‐tumor effects of the USP10 inhibitor spautin‐1, both alone and in combination with the Trop‐2 directed antibody‐drug conjugate, SG, in a TNBC 4T1 model engineered to express human TROP2. Here, VTCN1 is linked to neoplasm.